Market closedNon-fractional
AlloVir/ALVR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About AlloVir
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
Ticker
ALVR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Waltham, United States
Employees
15
Website
www.allovir.com
AlloVir Metrics
BasicAdvanced
$87M
Market cap
-
P/E ratio
-$1.64
EPS
0.78
Beta
-
Dividend rate
Price and volume
Market cap
$87M
Beta
0.78
Financial strength
Current ratio
18.48
Quick ratio
18.379
Long term debt to equity
13.324
Total debt to equity
15.229
Management effectiveness
Return on assets (TTM)
-51.82%
Return on equity (TTM)
-114.36%
Valuation
Price to book
0.73
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-0.615
Growth
Earnings per share change (TTM)
-16.99%
3-year earnings per share growth (CAGR)
-9.05%
What the Analysts think about AlloVir
Analyst Ratings
Majority rating from 5 analysts.
AlloVir Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$30M
-49.33%
Profit margin
0.00%
NaN%
AlloVir Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.48
-$0.39
-$0.36
-$0.26
-
Expected
-$0.45
-$0.42
-$0.43
-$0.16
-$0.09
Surprise
6.67%
-6.25%
-15.89%
65.96%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AlloVir stock?
AlloVir (ALVR) has a market cap of $87M as of July 27, 2024.
What is the P/E ratio for AlloVir stock?
The price to earnings (P/E) ratio for AlloVir (ALVR) stock is 0 as of July 27, 2024.
Does AlloVir stock pay dividends?
No, AlloVir (ALVR) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next AlloVir dividend payment date?
AlloVir (ALVR) stock does not pay dividends to its shareholders.
What is the beta indicator for AlloVir?
AlloVir (ALVR) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell AlloVir stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.